April 3, 2015 Eiger BioPharmaceuticals, Inc.Employment Agreement • December 14th, 2015 • Celladon Corp • Biological products, (no disgnostic substances)
MERGER INCENTIVE BONUS AGREEMENTMerger Incentive Bonus Agreement • December 14th, 2015 • Celladon Corp • Biological products, (no disgnostic substances) • California
This Merger Incentive Bonus Agreement (the “Agreement”) is made effective as of November 18, 2015 (the “Effective Date”) between Celladon Corporation (the “Company”), and Andrew Jackson (the “Employee”).
LICENSE AGREEMENTLicense Agreement • December 14th, 2015 • Celladon Corp • Biological products, (no disgnostic substances) • Delaware
This LICENSE AGREEMENT (the “Agreement”) is entered into on May 1st, 2015 (the “Effective Date”) between NIPPON KAYAKU CO., LTD., a Japanese corporation with its principal place of business at 1-1, Marunouchi 2-chome, Chiyoda-ku, Tokyo 100-0005, Japan (“KAYAKU”), and EICCOSE PHARMACEUTICALS, LLC, a Delaware corporation with its principal place of business at 1115 Lafayette St., Santa Clara, CA 95050, USA (“EICCOSE”). KAYAKU and EICCOSE are sometimes referred to herein individually as the “Party”and collectively as the “Parties.”
EXCLUSIVE AGREEMENTExclusive Agreement • December 14th, 2015 • Celladon Corp • Biological products, (no disgnostic substances) • California
This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and Eiccose, LLC (“Eiccose”), a Delaware limited liability company having a principal place of business at 1115 Lafayette Street, Santa Clara, CA 95050, is effective on the 27th day of October 2015 (“Effective Date”).
LICENSE AGREEMENTLicense Agreement • December 14th, 2015 • Celladon Corp • Biological products, (no disgnostic substances) • New York
This LICENSE AGREEMENT (the “Agreement”) is made and effective as of either the date of execution by the last Party to sign below (the “Effective Date”), by and between EB Pharma, LLC.,a company organized and existing under the laws of the State of Delaware having a business address at 1115 Lafayette Street, Santa Clara, CA 95050 (“EBP”), and Janssen Pharmaceutica NV, a company organized and existing under the laws of Belgium having a business address at Turnhoutseweg 30, 2340 Beerse, Belgium (“Janssen”). EBP and Janssen are each referred to individually as a “Party” and together as the “Parties.”
SUBSCRIPTION AGREEMENTSubscription Agreement • December 14th, 2015 • Celladon Corp • Biological products, (no disgnostic substances) • Delaware
This SUBSCRIPTION AGREEMENT (this “Agreement”) is dated as of November 18, 2015, by and among Eiger BioPharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser listed on Annex A hereto and a signatory hereto (each, including its successors and permitted assigns, a “Purchaser” and collectively, the “Purchasers”).
ASSET PURCHASE AGREEMENTAsset Purchase Agreement • December 14th, 2015 • Celladon Corp • Biological products, (no disgnostic substances) • Delaware
THIS ASSET PURCHASE AGREEMENT (this “Agreement”) is made as of December 8, 2010 (the “Effective Date”), by and among Eiger Group International, Inc., a Delaware corporation (“Seller”), and Eiger BioPharmaceuticals, Inc. (“Buyer”). Buyer and Seller may be referred to herein individually as a “Party” and collectively as the “Parties”. Certain other capitalized terms used in this Agreement are defined in Section 1.
EXCLUSIVE AGREEMENTExclusive Agreement • December 14th, 2015 • Celladon Corp • Biological products, (no disgnostic substances) • California
This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and Eiccose, LLC (“Eiccose”), a Delaware limited liability company having a principal place of business at 1115 Lafayette Street, Santa Clara, CA 95050, is effective on the 1st day of May 2015 (“Effective Date”).
ASSET PURCHASE AGREEMENT among: EIGER BIOPHARMACEUTICALS, INC., a Delaware corporation; and TRACEY MCLAUGHLIN AND COLLEEN CRAIG Dated as of September 25, 2015Asset Purchase Agreement • December 14th, 2015 • Celladon Corp • Biological products, (no disgnostic substances) • California
THIS ASSET PURCHASE AGREEMENT is entered into, effective as of September 25, 2015 (the “Effective Date”), by and between EIGER BIOPHARMACEUTICALS, INC., a Delaware corporation (“Purchaser”) and TRACEY MCLAUGHLIN AND COLLEEN CRAIG (each individually, “Seller”, collectively, “Sellers”). Purchaser and Sellers are referred to herein collectively as the “Parties” and individually as a “Party.” Certain other capitalized terms used in this Agreement are defined in Exhibit A.
December 5, 2008 Eiger Pharmaceuticals, Inc.Employment Agreement • December 14th, 2015 • Celladon Corp • Biological products, (no disgnostic substances)
LICENSE AGREEMENTLicense Agreement • December 14th, 2015 • Celladon Corp • Biological products, (no disgnostic substances) • New York
THIS LICENSE AGREEMENT (this “Agreement”), dated as of September 3, 2010, is by and between SCHERING CORPORATION, a New Jersey corporation having its principal place of business at 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 (hereinafter referred to as “Schering”) and Eiger Biopharmaceuticals, Inc., a corporation organized and existing under the laws of the state of Delaware and having its principal place of business at 3350 W Bayshore Road, Suite 120, Palo Alto, CA 94303 (hereinafter referred to as “Licensee”). Schering and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
ContractLease • December 14th, 2015 • Celladon Corp • Biological products, (no disgnostic substances) • California
THIS LEASE is made and entered into this day of March 2015, by and between JTC, a California general partnership, located at (hereinafter called “Lessor”), and Eiger BioPharmaceuticals, Inc., located at PO Box 430, San Carlos, CA 94070 (hereinafter called “Lessee”), for the promises and on the terms and conditions described herein.
ASSET PURCHASE AGREEMENT among: EIGER BIOPHARMACEUTICALS, INC. a Delaware corporation; and EICCOSE, LLC, a Delaware limited liability company Dated as of October 29, 2015Asset Purchase Agreement • December 14th, 2015 • Celladon Corp • Biological products, (no disgnostic substances) • Delaware
THIS ASSET PURCHASE AGREEMENT is entered into as of October 29, 2015, by and between EIGER BIOPHARMACEUTICALS, INC., a Delaware corporation (“Purchaser”) and EICCOSE, LLC, a Delaware limited liability company (“Seller”). Purchaser and Seller are referred to herein collectively as the “Parties” and individually as a “Party.” Certain other capitalized terms used in this Agreement are defined in Exhibit A. For clarity, Purchaser shall include any assignee, successor-in-interest or remaining entity possessing the Designated Assets (as defined below) in the event of any merger, reorganization or other similar acquisition transaction.
